Mind Medicine (MNMD.US) was first covered by Leerink Partners, which gave it an superior market rating, with a target price of $20.00.
Zhitong FinanceApr 15 22:31
Leerink Partners Initiates Coverage On Mind Medicine With Outperform Rating, Announces Price Target of $20
BenzingaApr 15 22:30
Mind Medicine Analyst Ratings
BenzingaApr 15 22:28
Mind Medicine Analyst Ratings
BenzingaMar 14 19:17
HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $75 Price Target
BenzingaMar 14 19:18
Mind Medicine Analyst Ratings
BenzingaMar 8 18:34
Mind Medicine Analyst Ratings
BenzingaMar 8 00:34
HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $75 Price Target
BenzingaMar 2 03:14
Mind Medicine Analyst Ratings
BenzingaMar 2 03:12
Mind Medicine Analyst Ratings
BenzingaMar 1 01:13
RBC Lifts Price Target on Mind Medicine (MindMed) to $15 From $14, Notes Imminent Durability Data; Outperform, Speculative Risk Kept
MT NewswiresFeb 29 20:52
Mind Medicine (MMED) Receives a Buy From Maxim Group
TipRanksDec 16, 2023 04:11
Maxim Group Maintains Their Buy Rating on Mind Medicine (MMED)
TipRanksNov 4, 2023 23:00
RBC Capital Reiterates Outperform on Mind Medicine, Maintains $7 Price Target
BenzingaOct 23, 2023 23:45
Mind Medicine Analyst Ratings
BenzingaOct 23, 2023 23:43
Mind Medicine Analyst Ratings
BenzingaAug 22, 2023 21:55
Mind Medicine (MMED) Gets a Buy Rating From H.C. Wainwright
TipRanksAug 4, 2023 23:50
Mind Medicine Analyst Ratings
BenzingaAug 4, 2023 20:13
RBC Raises Price Target on Mind Medicine (MindMed) to $7 From $5, Maintains Outperform, Speculative Risk
MT NewswiresAug 4, 2023 19:49
RBC Capital Reiterates Outperform on Mind Medicine, Maintains $5 Price Target
BenzingaJul 10, 2023 20:33
No Data
No Data